<DOC>
	<DOCNO>NCT01200810</DOCNO>
	<brief_summary>This partially randomize phase II trial study well give bicalutamide together RO4929097 work treat patient previously treat prostate cancer . Androgens cause growth prostate cancer cell . Antihormone therapy , bicalutamide , may lessen amount androgen make body . RO4929097 may stop growth tumor cell block enzymes need cell growth . Giving bicalutamide together RO4929097 may effective treatment prostate cancer</brief_summary>
	<brief_title>Bicalutamide RO4929097 Treating Patients With Previously Treated Prostate Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine difference time PSA progression patient adenocarcinoma prostate rise PSA definitive local therapy treat bicalutamide v without gamma-secretase/Notch signal pathway inhibitor RO4929097 ( RO4929097 ) . SECONDARY OBJECTIVES : I . To determine proportion patient arm achieve complete response ( PSA ) combination phase . II . To determine proportion patient arm PSA progression combination phase . III . To determine time PSA nadir combination phase patient arm . IV . To determine time PSA progression combination phase patient arm . V. To determine time PSA progression observation phase . VI . To determine proportion patient PSA progression observation phase . VII . To assess safety tolerability gamma-secretase inhibitor RO4929097 combination bicalutamide . VIII . To evaluate expression target gamma secretase inhibitor prostate tissue microarray . IX . To collect serum future evaluation soluble marker gamma-secretase inhibition angiogenesis . OUTLINE : This multicenter study . INDUCTION PHASE : All patient receive induction therapy comprise oral bicalutamide daily least 16 week . Patients whose PSA decline least 50 % continue randomization phase . RANDOMIZATION PHASE : Patients stratify accord prior therapy ( radiotherapy v surgery ) randomize 1 2 treatment arm . ARM I : Patients receive oral placebo daily day 1-3 , 8-10 , 15-17 . Treatment repeat every 21 day 18 course absence PSA progression . ARM II : Patients receive oral gamma-secretase/Notch signal pathway inhibitor RO4929097 ( RO4929097 ) daily day 1-3 , 8-10 , 15-17 . Treatment repeat every 21 day 18 course absence PSA progression . Patients disease progression continue combination phase . Patients disease progression undergo image study verify absence metastatic disease continue combination phase . COMBINATION PHASE : All patient receive oral bicalutamide daily day 1-21 oral RO4929097 daily day 1-3 , 8-10 , 15-17 . Courses repeat every 21 day 12 month absence disease progression unacceptable toxicity . Blood tumor tissue sample may collect periodically correlative study . After completion study treatment , patient follow every 6 week 12 month .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<criteria>Histologically confirm prostate cancer Stage D0 OR D1 disease ( i.e. , tumor originally diagnose limited prostate regional lymph node ) Has rise PSA value definitive local therapy ( i.e. , prostatectomy radiotherapy ) radiographic evidence disease PSA progression local treatment : PSA value patient surgery must ≥ 0.2 ng/mL , determine two measurement , ≥ 1 month apart ≥ 6 month prostatectomy PSA value patient radiotherapy must ≥ 2.0 ng/mL nadir PSA achieve radiotherapy , determine two measurement 1 month apart ≥ 6 month completion radiotherapy treatment ( patient receive adjuvant salvage radiotherapy prostatectomy must PSA ≥ 0.2 ng/mL ) The first two PSA value , along third ( study baseline ) value must rise ( i.e. , must overall rise trajectory , third value lower first value ) No metastatic disease baseline bone scan CT scan abdomen/pelvis ECOG performance status 02 Life expectancy ≥ 6 month WBC ≥ 3,000/mm^3 ANC ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 9 g/dL Serum creatinine ≤ 1.5 time upper limit normal ( ULN ) OR creatinine clearance ≥ 40 mL/min patient creatinine level normal Bilirubin normal AST and/or ALT ≤ 2.5 time ULN Serum total testosterone level ≥ 150 ng/dL No uncontrolled electrolyte abnormality include hypocalcemia , hypomagnesemia , hyponatremia , hypophosphatemia , hypokalemia , define less low limit normal despite adequate electrolyte supplementation Fertile patient must use two effective form contraception ( i.e. , barrier contraception one method contraception ) 1 week , , ≥ 12 month completion study treatment Able swallow tablet No malabsorption syndrome condition would interfere intestinal absorption No uncontrolled concurrent illness include , limited , follow : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris A history torsades de pointes Cardiac arrhythmia chronic , stable atrial fibrillation Psychiatric illness social situation would limit compliance study requirement Baseline QTc ≤ 450 msec No serologic positivity acute hepatitis A , acute chronic hepatitis B , acute chronic hepatitis C No history liver disease form hepatitis cirrhosis No HIVpositive patient combination antiretroviral therapy No serious concurrent systemic disorder would compromise safety patient compromise patient 's ability complete study , discretion investigator No history allergic reaction attribute compound similar chemical biologic composition gammasecretase inhibitor RO4929097 bicalutamide Patients may donate sperm blood ≥ 12 month completion study treatment No concurrent medication food may interfere metabolism RO4929097 include grapefruit freshsqueezed grapefruit juice Recovered adverse event &lt; CTCAE grade 2 At least 3 month since prior concurrent androgendeprivation therapy ( ADT ) Hormoneablative treatment allow neoadjuvant set set primary salvage radiotherapy No 36 month neoadjuvant/ adjuvant ADT More 4 week since prior chemotherapy radiotherapy ( 6 week nitrosoureas mitomycin C ) More 4 week since prior concurrent estrogen , estrogenlike substance ( i.e. , PCSPES , saw palmetto , herbal product may contain phytoestrogens ) , hormonal therapy ( include flutamide , nilutamide , finasteride , ketoconazole , systemic corticosteroid , megestrol acetate , cyproterone acetate ) No concurrent investigational agent No concurrent medication narrow therapeutic index metabolize cytochrome P450 ( CYP450 ) , include warfarin sodium ( Coumadin® ) No concurrent medication strong inducers/inhibitors substrates CYP3A4 No investigational commercial agent therapy administer intent treat patient 's malignancy , include chemotherapy , immunotherapy , hormonal cancer therapy , radiotherapy , surgery cancer No concurrent hormonal therapy leuteinizing hormonereleasing hormone ( LHRH ) agonist therapy ( e.g. , leuprolide goserelin ) LHRH antagonist ( e.g. , abarelix ) No concurrent growth factor ( e.g. , GCSF ) , pack RBC transfusion , platelet transfusion No concurrent antiarrhythmic medication know prolong QTc</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>